M&T Bank Corp Buys 8,955 Shares of IQVIA Holdings Inc. (NYSE:IQV)

M&T Bank Corp grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 8.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,197 shares of the medical research company’s stock after purchasing an additional 8,955 shares during the quarter. M&T Bank Corp’s holdings in IQVIA were worth $26,402,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Riverview Trust Co acquired a new position in shares of IQVIA in the first quarter valued at about $25,000. UMB Bank N A MO acquired a new position in shares of IQVIA in the fourth quarter valued at about $26,000. Dividend Assets Capital LLC acquired a new stake in IQVIA during the first quarter worth about $27,000. Johnson Financial Group Inc. acquired a new stake in IQVIA during the fourth quarter worth about $34,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in IQVIA during the fourth quarter worth about $38,000. 87.12% of the stock is owned by institutional investors.

IQVIA Stock Up 0.2 %

Shares of NYSE IQV opened at $234.74 on Friday. The company has a 50 day simple moving average of $216.94 and a 200 day simple moving average of $223.66. The firm has a market cap of $43.78 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 2.14 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $194.67 and a 1 year high of $285.61. The company has a debt-to-equity ratio of 2.36, a current ratio of 0.96 and a quick ratio of 0.96.

IQVIA (NYSE:IQV – Get Rating) last issued its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.22. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.49 billion. During the same quarter last year, the business earned $1.94 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, research analysts forecast that IQVIA Holdings Inc. will post 9.42 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Barclays reduced their price objective on shares of IQVIA from $240.00 to $236.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 13th. Piper Sandler upgraded shares of IQVIA from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $231.00 to $255.00 in a research note on Thursday, April 28th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of IQVIA from $250.00 to $290.00 and gave the stock a “buy” rating in a research note on Tuesday, April 12th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Finally, Evercore ISI raised their price target on shares of IQVIA from $265.00 to $275.00 in a research note on Friday, July 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $274.44.

IQVIA Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.